These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Malaria antibody levels in patients with nasopharyngeal carcinoma. Yadav M; Prasad U Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462 [TBL] [Abstract][Full Text] [Related]
6. Histological types of nasopharyngeal carcinoma in an intermediate risk area. Cammoun M; Ellouz R; Behi J; Attia RB IARC Sci Publ (1971); 1978; (20):13-26. PubMed ID: 215511 [TBL] [Abstract][Full Text] [Related]
7. Histological types of nasopharyngeal carcinoma as compared to EBV serology. Krueger GR; Kottaridis SD; Wolf H; Ablashi DV; Sesterhenn K; Bertram G Anticancer Res; 1981; 1(4):187-94. PubMed ID: 6285799 [TBL] [Abstract][Full Text] [Related]
8. Classification of lymphocytes in nasopharyngeal carcinoma (NPC) biopsies. Jondal M; Klein G Biomedicine; 1975 Jun; 23(5):163-5. PubMed ID: 1081410 [TBL] [Abstract][Full Text] [Related]
9. Nasopharyngeal carcinoma and Epstein-Barr virus. I. Factors related to the anti-VCA antibody. Lynn T; Tu S; Hirayama T; Kawamura A Jpn J Exp Med; 1973 Apr; 43(2):121-33. PubMed ID: 4352111 [No Abstract] [Full Text] [Related]
10. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Liu MT; Yeh CY Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898 [TBL] [Abstract][Full Text] [Related]
11. Clinical aspects and natural history of nasopharyngeal carcinoma in Western Europe. Cachin Y; Schwaab G; Sancho-Garnier H; Marandas P IARC Sci Publ (1971); 1978; (20):131-45. PubMed ID: 215512 [No Abstract] [Full Text] [Related]
12. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805 [TBL] [Abstract][Full Text] [Related]
13. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma. Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156 [TBL] [Abstract][Full Text] [Related]
14. A prospective evaluation of patients with nasopharyngeal carcinoma: an overview. Neel HB J Otolaryngol; 1986 Jun; 15(3):137-44. PubMed ID: 3014165 [TBL] [Abstract][Full Text] [Related]
15. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups. Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990 [TBL] [Abstract][Full Text] [Related]
16. Serologic diagnosis of nasopharyngeal carcinoma. A double-blind study of four EB virus antibodies with evaluation by sequential discrimination. Cai WM; Li YW; Wu B; Liu YY; Hu YH; Gu XZ; Liu HY; Wang GD Int J Radiat Oncol Biol Phys; 1983 Dec; 9(12):1763-8. PubMed ID: 6319338 [TBL] [Abstract][Full Text] [Related]
17. Nasopharyngeal carcinoma and Epstein-Barr virus. II. Clinical course and the anti-VCA antibody. Lynn T; Tu S; Hirayama T; Kawamura A Jpn J Exp Med; 1973 Apr; 43(2):135-44. PubMed ID: 4352112 [No Abstract] [Full Text] [Related]
18. Histopathological types of nasopharyngeal carcinoma in a low-risk area: Japan. Sugano H; Sakamoto G; Sawaki S; Hirayama T IARC Sci Publ (1971); 1978; (20):27-39. PubMed ID: 215515 [TBL] [Abstract][Full Text] [Related]
19. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in nasopharyngeal carcinoma. Chatani M; Teshima T; Inoue T; Yoshino K; Ikegami N; Hirai K; Shimakage M Laryngoscope; 1991 Jun; 101(6 Pt 1):626-9. PubMed ID: 1645832 [TBL] [Abstract][Full Text] [Related]